Xuanzhu Biopharmaceutical Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-556.43	-300.56	-461.58	-162.45
Depreciation & Amortization	33.18	31.44	18.14	15.47
Other Amortization	0.58	0.73	-	-
Loss (Gain) From Sale of Assets	7.57	-1.02	-	-
Loss (Gain) From Sale of Investments	-9.16	-15.93	-	-
Stock-Based Compensation	402.9	72.27	-	-
Other Operating Activities	2.14	3.45	32.01	-60.66
Change in Accounts Receivable	-0.19	-	-	-
Change in Inventory	3.35	-12.87	-	-
Change in Accounts Payable	29.67	29.48	-	-
Change in Unearned Revenue	-3.55	-	-	-
Change in Other Net Operating Assets	-37.16	77.07	-	-
Operating Cash Flow	-127.09	-115.95	-411.43	-207.65
Capital Expenditures	-0.51	-1.74	-75.99	-57.26
Sale of Property, Plant & Equipment	-	0.01	0.02	180.46
Cash Acquisitions	-	-	-131	-
Sale (Purchase) of Intangibles	-73.05	-144.61	-	-
Investment in Securities	205.49	191.08	250.61	-292.93
Other Investing Activities	-	-	5.14	-5
Investing Cash Flow	131.93	44.73	48.77	-174.73
Long-Term Debt Issued	-	-	200	-
Long-Term Debt Repaid	-5.26	-7.58	-200	-8
Net Debt Issued (Repaid)	-5.26	-7.58	-	-8
Issuance of Common Stock	-	-	866.21	925.93
Common Dividends Paid	-	-	-0.45	-0.19
Other Financing Activities	-7.16	-2.33	-8.08	-3.23
Financing Cash Flow	-12.43	-9.9	857.69	914.51
Foreign Exchange Rate Adjustments	-0.05	-0.1	-0.01	0.02
Net Cash Flow	-7.64	-81.22	495.01	532.16
Free Cash Flow	-127.6	-117.69	-487.42	-264.9
Free Cash Flow Margin	-424.00%	-405831.03%	-	-
Free Cash Flow Per Share	-0.28	-0.26	-1.24	-
Cash Income Tax Paid	0.01	0.01	7.87	2.97
Levered Free Cash Flow	20.98	-	-336.77	-171.5
Unlevered Free Cash Flow	21.17	-	-336.08	-171.26
Change in Working Capital	-7.87	93.68	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.